These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 22089463

  • 1. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Mack M, Kremer J.
    J Rheumatol; 2011 Dec; 38(12):2572-80. PubMed ID: 22089463
    [Abstract] [Full Text] [Related]

  • 2. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 3. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME, GO-FURTHER Investigators.
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 5. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S, Hsia EC.
    J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
    [Abstract] [Full Text] [Related]

  • 6. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
    Huffstutter JE, Kafka S, Brent LH, Matucci-Cerinic M, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ.
    Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
    [Abstract] [Full Text] [Related]

  • 7. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [Abstract] [Full Text] [Related]

  • 8. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
    Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW, Nasonov E, Durez P, Delaet I, Teng J, Alten R.
    J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
    [Abstract] [Full Text] [Related]

  • 10. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [Abstract] [Full Text] [Related]

  • 11. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 14. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC.
    Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU.
    Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
    [Abstract] [Full Text] [Related]

  • 20. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.